|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD151 ablation sensitized multiple tumor cell types to several anti-cancer drugs (e.g., gefitinib and camptothecin), thus increasing apoptosis, as seen using cleaved caspase-3, cleaved PARP (poly (ADP-ribose) polymerase), annexin V, and propidium iodide staining assays.
|
30778617 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As a control, MRI was also obtained at 4 h after injection of USPIO without Annexin V. The ratio of tumor signal intensity (SI) on post-MRI for that on pre-MRI (Post/Pre-SI ratio) was calculated.
|
30282879 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Then, CCK-8, wound healing, Transwell and annexin V-PI assays were employed to evaluate the tumor inhibitory effects of Trop2-IgG on OC in vitro, while tumor-bearing mice were constructed to examine the tumor inhibitory effects of Trop2-IgG on OC in vivo.
|
30879767 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The effects of NKX2-8 deletion and the fatty acid oxidation (FAO) antagonist Perhexiline on chemoresistance were examined by Annexin V and colony formation in vitro, and via an intraperitoneal tumor model in vivo.
|
31047858 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Annexin V staining was used to compare the percent of tumor cell apoptosis in the presence of opioid-pretreated and untreated natural killer cells.
|
30801358 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MTT assay and Annexin V staining were used to detect the effects of miR-182 on tumor cells proliferation.
|
31519771 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In order to further enhance the therapeutic efficacy, anti-CD73 and anti-OX40 immunostimulants were combined with mCTH-ANXA5, resulting in an increase of survival by 100% from 12 to 24 days post-therapy and decrease tumor burden in mice with orthotopic metastatic ovarian cancer.
|
29574275 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cell apoptosis and rate of tumor growth and volume were determined by Annexin V-FITC/PI staining and a xenotransplanted tumor model in nude mice.
|
29932870 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Nanotubes are specifically targeted to the tumour via the interaction of annexin V (AV) and phosphatidylserine, which is normally internalised on healthy tissue but externalised on tumours and the tumour vasculature.
|
29160225 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Consequently, we recorded that while miR-421 is significantly suppressing TMEM48 expression; it increased apoptotic and tumor suppressor players CASPASE 3, PTEN and TP53 in A549 line, which is consistent with Annexin V - PI results: 30,6% of A549 observed to be apoptotic - 68,5% of A549 was in GO/G1.
|
29906465 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In comparison with the noninvasive tumor M5-T2, proteomic analysis demonstrated the three invasive tumors F4-T2, F5-T1 and M5-T1 shared in common a very significant increase in the abundance of the multifunctional proteins galectin-3, prohibitin and annexin A5, and a decrease in proteins involved in cell adhesion, tumor suppression, or epithelial differentiation.
|
29662647 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Antitumor activities of Operculina turpathum extract (OTE) was investigated by MTT and clonogenic assay, effect on cell cycle and apoptosis induction by Annexin-V/propidium iodide (PI) staining and flow cytometry and invasive potential of the tumor was determined by matrigel assay.
|
28351666 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Functional assays, such as anchorage-independent growth, chicken chorioallantoic membrane (CAM) assay, transwell matrix penetration assay, and Annexin V-FITC and PI staining and a xenograft tumor model were used to determine the oncogenic role of GPR87 in human pancreatic cancer progression.
|
28288630 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data provided a possibility that Annexin V can be used as a novel angiogenesis inhibitor in tumor therapy.
|
28402934 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
For patients with colon cancer, annexin A5 expression in cancer tissues is related to lymph node metastasis and tumor grade.
|
29093625 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ANXA5 level is linked to in vitro and in vivo tumor malignancy and lymphatic metastasis of murine hepatocarcinoma cell.
|
26615672 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, assay of cell viability, quantitative real-time PCR, Western blot, annexin V/propidium iodide assay, flow cytometry and tumor-xenograft model were applied to elucidate the mechanism of Lfcin-B on non-small cell lung cancer NCI-H460 (H460) cells.
|
24691828 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Analysis of the tumors from the Flii overexpressing mice showed reduced caspase I and annexin V expression suggesting Flii may negatively regulate apoptosis within these tumors.
|
26497552 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Livin expression and apoptosis for tumor hypoxic cells derived from human glioblastoma xenografts or in vitro hypoxic stress-treated glioblastoma cells were determined by Western blotting, immunofluorescence imaging, and annexin V staining assay.
|
25370472 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Increasing annexin A5 size prolongs circulation times and increases tumor uptake, but decreases contribution of PS-targeting to tumor uptake and abolishes power to report efficacy of therapy.
|
24801051 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Annexin V provided this recombinant protein with higher efficacy, while leaving tumor specificity of TRAIL unchanged since TP8 had no effects on normal cells.
|
24356445 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Anchorage-independent growth, chicken chorioallantoic membrane, Transwell matrix invasion and Annexin V-binding assays, and a xenograft tumor model were used to determine the role of miR-138 in ESCC progression.
|
23319823 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cytotoxicity would be localized to the site of the tumor using a protein fusion of purine nucleoside phosphorylase (PNP) and annexin V. Annexin V acts as the tumor-targeting component of the fusion protein as it has been shown to bind to phosphatidylserine expressed externally on cancer cells and the endothelial cells of the tumor vasculature, but not normal vascular endothelial cells.
|
24098491 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In A2780 OvCa cell line expressing HSD17B12, siRNA knockdown of the enzyme was performed, and its effects on tumor cell growth and Annexin V binding were determined.
|
22903146 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Compared with moderately and well-differentiated tumors, there was a significant increase in ANXA5 expression in poorly differentiated tumors.
|
22971941 |
2012 |